1. Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
- Author
-
Yasuhiro Takeuchi, Keita Tatsushima, Hiroshi Nishioka, Noriaki Fukuhara, Tomoko Mizuno, Naoko Inoshita, Akira Takeshita, and Shozo Yamada
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Adenoma ,medicine.medical_treatment ,chemistry.chemical_compound ,Refractory ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Receptors, Somatostatin ,Pituitary ACTH Hypersecretion ,education ,education.field_of_study ,Somatostatin receptor-5 ,Somatostatin receptor ,business.industry ,General Medicine ,Cushing's disease ,medicine.disease ,Pasireotide ,Radiation therapy ,chemistry ,Immunohistochemistry ,Somatostatin ,business - Abstract
Pasireotide, which has a high affinity for somatostatin receptor (SSTR) 5, has attracted attention as a new treatment for refractory Cushing's disease. The patient was a 28-year-old man. He had refractory Cushing's disease and underwent multiple surgeries, radiotherapy, and medication therapy. An examination of the adenoma by immunohistochemistry revealed a low SSTR5 expression. An USP8 mutation was not detected by reverse transcription polymerase chain reaction. Although we administered pasireotide, it was ineffective. While a further investigation is necessary, the analysis of SSTR5 expression may support the prediction of the efficiency of pasireotide for Cushing's disease. We report this case as a useful reference when considering whether or not to use pasireotide for refractory corticotroph adenomas.
- Published
- 2022